BTIG analyst Thomas Shrader has maintained their neutral stance on INMB stock, giving a Hold rating yesterday.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Thomas Shrader has given his Hold rating due to a combination of factors related to Inmune Bio’s recent clinical trial outcomes and the broader market environment. The company’s trial for Xpro in Alzheimer’s Disease (AD) faced challenges, including a lack of clear direction and management’s indication of shifting focus to other programs. The trial results showed only trends in a subset of patients with inflammation markers, and the trial protocols were less stringent in early phases, leading to the inclusion of patients without AD-related plaques.
Furthermore, the primary endpoint was not met, with the placebo showing more favorable results in the general population, although some positive effects were observed in a smaller subset of patients. Despite interesting biomarker signals, the trial’s size and scope were insufficient to draw definitive conclusions. The potential for future partnerships or financing could change the outlook, but for now, the uncertainties and limited trial success justify a Hold rating.